Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children
- PMID: 2721111
- DOI: 10.1038/clpt.1989.74
Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children
Abstract
The feasibility and reliability of simultaneously determining debrisoquin oxidation and N-acetylation phenotypes was assessed in children with use of two innocuous substrate probes given by mouth, 30 mg dextromethorphan (Pertussin ES) and 25 to 46 mg caffeine (Coca-Cola beverage). Twenty-six children and adolescents (aged 3 to 21 years) were studied three times, once with each substrate given alone and once with the two substrates given together. Urine was collected for 4 hours, and the molar urinary metabolic ratios for dextromethorphan:dextrorphan and for two caffeine metabolites (AFMU:1X) were determined by HPLC ultraviolet assays. The urinary metabolic ratios for both substrates were not significantly different when the substrates were given alone compared with when they were given together. There also was no difference in either the oxidation or acetylation phenotype assignments when the two substrates were given alone and when they were given together. No adverse effects were observed. We conclude that dextromethorphan and caffeine can be given together to simultaneously determine oxidation and acetylation phenotypes and can thereby provide an innocuous, noninvasive method for the assessment of polymorphic drug metabolism in various pediatric populations.
Similar articles
-
Assessment of the debrisoquin and dextromethorphan phenotyping tests by gaussian mixture distributions analysis.Clin Pharmacol Ther. 1989 Mar;45(3):328-33. doi: 10.1038/clpt.1989.36. Clin Pharmacol Ther. 1989. PMID: 2920506
-
Pharmacogenetics of dextromethorphan O-demethylation in man.Xenobiotica. 1986 May;16(5):421-33. doi: 10.3109/00498258609050249. Xenobiotica. 1986. PMID: 3739367
-
Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.Clin Pharmacol Ther. 1985 Dec;38(6):618-24. doi: 10.1038/clpt.1985.235. Clin Pharmacol Ther. 1985. PMID: 4064464
-
Genetically determined variability in acetylation and oxidation. Therapeutic implications.Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003. Drugs. 1985. PMID: 2859977 Review.
-
The pharmacogenetics of antiarrhythmic drugs.Ann N Y Acad Sci. 1984;432:69-74. doi: 10.1111/j.1749-6632.1984.tb14509.x. Ann N Y Acad Sci. 1984. PMID: 6395768 Review. No abstract available.
Cited by
-
Isolation and Identification of 3,4-Seco-Solanidine-3,4-dioic acid (SSDA) as a Urinary Biomarker of Cytochrome P450 2D6 (CYP2D6) Activity.Drug Metab Dispos. 2022 Jul 25;50(10):1342-51. doi: 10.1124/dmd.122.000957. Drug Metab Dispos. 2022. PMID: 35878926 Free PMC article.
-
Clinical pharmacokinetics of atomoxetine.Clin Pharmacokinet. 2005;44(6):571-90. doi: 10.2165/00003088-200544060-00002. Clin Pharmacokinet. 2005. PMID: 15910008 Review.
-
Ontogeny of Pediatric Pharmacogenetics: Celebrating the Past and Vision for the Future.J Pediatr Pharmacol Ther. 2022;27(1):4-11. doi: 10.5863/1551-6776-27.1.4. Epub 2021 Dec 22. J Pediatr Pharmacol Ther. 2022. PMID: 35002553 Free PMC article. No abstract available.
-
Pharmacokinetics in the child.Environ Health Perspect. 1994 Dec;102 Suppl 11(Suppl 11):111-7. doi: 10.1289/ehp.94102s11111. Environ Health Perspect. 1994. PMID: 7737035 Free PMC article. Review.
-
Influence of hydroxychloroquine on the bioavailability of oral metoprolol.Br J Clin Pharmacol. 2000 Jun;49(6):549-54. doi: 10.1046/j.1365-2125.2000.00197.x. Br J Clin Pharmacol. 2000. PMID: 10848718 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical